Genta sued over NDA withdrawal
Article Abstract:
A lawsuit was registered against the biopharmaceutical company Genta from New Jersey on 4th May 2004 for not clearly specifying the effect of Genasense drug utilized for recurring type of metastatic melanoma. After ten days when the Oncologic Drugs Advisory Committee (ODAC) did not approve the same, Genta withdrew this new drug application (NDA) which has led to a fall in the market value of Genta.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Maturing biotechs turn to pharma's markets
Article Abstract:
The foray into primary care, which is highly unusual for a small company, reflects maturation among biotechs, based on their ability to amass and efficiently use financial and commercial resources. Sepracor's focus on primary care market is an example of a shift in strategy at certain maturing biotech companies to target broader, highly competitive markets traditionally served by big pharma.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Redesigner drugs
Article Abstract:
Some biotech companies are placing drug redesign at the centers of their business plans with biotech steadily uncovering more drug targets and mechanisms, and finding new ways to exploit them. Also, several blockbuster drugs are losing patent protection in the next couple of years, which provides opportunities for companies to recast off-patent drugs into so-called second-generation drugs.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Reverse mergers attract top-tier biotechs in sluggish IPO market. More biotechs gamble on convertibles
- Abstracts: The number on biotech indexes. Putting biotech risk in its place. Going short on biotech
- Abstracts: Apache downed in Iraq by unknown weapon. Marine Aviation feels stress of war. Rocket test may have damaged super cobra
- Abstracts: Genome sequence of the bioplastic-producing "Knallgas" bacterium Ralstonia eutropha H16. Complete genome sequence of the acetic acid bacterium gluconobacter oxydans
- Abstracts: US to safeguard 'dual-use' biology research. When less is more